BillionToOne is a precision diagnostics company with the mission to make molecular diagnostics more accurate, efficient, and accessible. Operating in the rapidly evolving field of genetic testing and disease detection, the company has positioned itself as a transformative force in both prenatal screening and oncology diagnostics. With trailing 12-month revenue of $305M and a current market capitalization of $3.62B, BillionToOne represents a significant success story in the molecular diagnostics sector.
How It Started
BillionToOne was founded in 2016 and is headquartered in Menlo Park, California. The company emerged from a fundamental problem in molecular diagnostics: the inability to accurately count DNA molecules at single-molecule levels, which limited disease detection capabilities. Founded by Oguzhan Atay and David Tsao, the team identified that traditional diagnostic methods lacked the precision necessary for breakthrough improvements in prenatal screening and cancer detection.
The solution came in the form of Quantitative Counting Templates™ (QCTs™), which enable counting DNA molecules with single base-pair precision. This proprietary technology unlocked entirely new possibilities for disease detection. The target audience includes expectant parents seeking comprehensive prenatal screening and cancer patients requiring therapy selection and response monitoring. Over 500,000 patients have received BillionToOne tests to date, and BillionToOne has grown from $0M to $125M ARR in the last approximately four years.
Competitive Advantage
BillionToOne maintains several key competitive advantages:
- Proprietary molecular counting platform: The company’s patented Quantitative Counting Technology™ (QCT™) molecular counting platform is the only multiplex technology that can accurately count DNA molecules at the single-molecule level.
- Comprehensive prenatal testing: UNITY Fetal Risk™ Screen is the first-and-only prenatal test of its kind. The test leverages fetal cell-free DNA to provide direct insights into fetal risk for aneuploidies and common recessively inherited conditions, such as sickle cell disease, spinal muscular atrophy, and cystic fibrosis, without requiring a blood sample from the male partner or amniocentesis.
- Superior oncology diagnostics: Northstar Select® achieves a 2–5x lower limit of detection compared to other assays on the market, and Northstar Response® is a methylation-based ctDNA assay with 10x greater precision than SNV-based assays.
- Established clinical validation: The company has demonstrated technical leadership through peer-reviewed publications confirming the accuracy and superiority of its methods over competing alternatives.
Marketing Techniques
BillionToOne employs a multi-channel marketing strategy tailored to healthcare professionals and expectant parents.
Clinical partnerships and collaborations: The company has established strategic partnerships with major healthcare infrastructure providers. BillionToOne announced a collaboration with Epic to expand prenatal and oncology testing across healthcare. These partnerships ensure integration into existing clinical workflows and broaden accessibility.
Scientific publication and thought leadership: BillionToOne builds credibility through the publication of clinical data in peer-reviewed journals. The company demonstrated technical leadership through CAP Accreditation and landmark data published in Genetics in Medicine and the American Journal of Hematology. These studies confirmed the high accuracy of single-gene NIPT in the general pregnancy population.
Medical conferences and professional education: The company actively participates in major healthcare conferences and webinars to educate clinicians about its products and clinical advantages, reaching specialists directly within their professional settings.
How BillionToOne Makes Money
The company’s product portfolio comprises UNITY, a portfolio of prenatal testing products that can conduct fetal risk analysis without requiring a paternal sample; Northstar Select, an ultrasensitive liquid biopsy test that provides insights into appropriate therapies for stage III or IV cancer patients; and Northstar Response, a tissue-free, pan-cancer, liquid biopsy test. Revenue is generated through laboratory testing fees paid by healthcare providers, insurers, and patients. The company operates as a Laboratory Developed Test (LDT) provider, processing blood samples and delivering results to clinicians and patients while maintaining margins through the operational efficiency enabled by its proprietary technology.
Market Share
| Competitor | Primary Focus | Market Position |
|---|---|---|
| BillionToOne (BLLN) | Prenatal and oncology | $3.62B market cap |
| Foundation Medicine | Cancer genomics | Established competitor |
| Myriad Genetics | Genetic testing | Established competitor |
| Guardant Health | Liquid biopsy | Established competitor |
| Natera | Prenatal and oncology | Established competitor |
Business Model Canvas of BillionToOne
Key Partners: Healthcare systems, insurance providers, clinical laboratories, Epic Systems, and research institutions
Key Activities: Molecular diagnostics testing, product development, clinical validation, regulatory compliance, and laboratory operations
Key Resources: Proprietary QCT molecular counting platform, CLIA-certified laboratory infrastructure, skilled R&D team, and an extensive patient database
Value Proposition: Unprecedented accuracy in disease detection through single-molecule counting, comprehensive prenatal screening without the need for paternal samples, and superior cancer therapy selection and monitoring capabilities
Customer Segments: Pregnant individuals seeking prenatal screening, cancer patients and their physicians, healthcare providers, clinical laboratories, and insurers
Channels: Direct laboratory testing, healthcare provider partnerships, hospital integration, and clinical education programs
Customer Relationships: Professional relationships with healthcare providers, ongoing clinical support, and patient engagement through results delivery
Revenue Streams: Laboratory testing fees from prenatal screening (UNITY products), oncology liquid biopsy testing (Northstar Select and Northstar Response), insurance reimbursement, and out-of-pocket patient fees
Cost Structure: Laboratory operations, R&D and product development, regulatory compliance and certification, clinical staffing, and marketing and professional education
Conclusion: Is It a Viable Business?
BillionToOne represents a highly viable and scalable business. The company demonstrates strong financial performance with trailing twelve-month revenue of $305M and operates in markets with significant growth potential. The current market capitalization of $3.62B reflects investor confidence in its long-term prospects. The company’s proprietary technology creates defensible competitive advantages, while its dual focus on prenatal and oncology markets diversifies revenue streams and reduces dependence on any single segment. Strategic partnerships with major healthcare systems such as Epic accelerate market penetration, and the growing adoption of precision medicine supports continued expansion. With strong clinical validation, regulatory certifications, and a proven management team, BillionToOne is well-positioned for sustained growth in the molecular diagnostics market.
Hi Friends, This is Swapnil, I am a content writer at startupsunion.com